U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H17NO2
Molecular Weight 231.2903
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENZOCLIDINE

SMILES

O=C(OC1CN2CCC1CC2)C3=CC=CC=C3

InChI

InChIKey=AHKAOMZZTQULDS-UHFFFAOYSA-N
InChI=1S/C14H17NO2/c16-14(12-4-2-1-3-5-12)17-13-10-15-8-6-11(13)7-9-15/h1-5,11,13H,6-10H2

HIDE SMILES / InChI

Molecular Formula C14H17NO2
Molecular Weight 231.2903
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Benzoclidine (Oxylidin) exerts tranquilizing and hypotensive actions. It reduces the excitability of the central nervous system, enhances the effect of hypnotic drugs, analgesics and local anesthetics, has a moderate antihypertensive effect, reduces the excitability of the vasomotor centers, has anti-arrhythmic activity. Benzoclidine is marke indicated for the treatment of anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Benzoclidine

Approved Use

Anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.
Primary
Benzoclidine

Approved Use

Anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.
Primary
Benzoclidine

Approved Use

Anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.
PubMed

PubMed

TitleDatePubMed
[ON THE RELATIONSHIP BETWEEN THE HYPOTENSIVE EFFECT OF OXYLIDIN AND ITS EFFECT ON CENTERS OF THE MEDULLA OBLONGATA AND CARDIAC ACTIVITY].
1964 Jan-Feb
[OXYLIDIN THERAPY OF PATIENTS WITH CEREBROVASCULAR DISEASES WITH MENTAL DISORDERS].
1965
[CLINICAL TESTING OF OXYLIDIN, A NEW HYPOTENSIVE AGENT, IN THE TREATMENT OF HYPERTENSION].
1965 Feb
[Experience in the treatment of hypertensive patients with oxylidin under polyclinical conditions].
1965 Nov

Sample Use Guides

Average therapeutic dose oral, subcutaneous and intramuscular injection 0.02 - 0.3 grams daily, the duration of treatment 3-8 weeks.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:00:10 GMT 2023
Edited
by admin
on Fri Dec 15 16:00:10 GMT 2023
Record UNII
G84189YY06
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENZOCLIDINE
INN  
INN  
Official Name English
3-QUINUCLIDINOL BENZOATE (ESTER)
Common Name English
3-QUINUCLIDINOL DL-FORM BENZOATE (ESTER) [MI]
Common Name English
NSC-760346
Code English
benzoclidine [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29756
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
Code System Code Type Description
SMS_ID
100000086387
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
CAS
66-93-3
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
SUPERSEDED
INN
3086
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
ChEMBL
CHEMBL121932
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
NSC
760346
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
FDA UNII
G84189YY06
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
NCI_THESAURUS
C77243
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
PUBCHEM
65630
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
MERCK INDEX
m9469
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY Merck Index
EVMPD
SUB05756MIG
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
CAS
16852-81-6
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID0046191
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
MESH
C000662
Created by admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY